GSK announces results evaluating its investigational monoclonal antibody, otilimab, for the treatment of hospitalised adult patients with COVID-19

GSK today announce results from the phase 2 proof of concept OSCAR study with otilimab, an investigational anti-GM-CSF monoclonal antibody.